Výsledky vyhledávání

Akademický článek

Arterial ammonia levels in the management of fulminant liver failure

Autor: Curry S, Remke S, Little E, Gerkin R, Manch R, Leibowitz A., Raschke R

Publikováno v: Southwest Journal of Pulmonary and Critical Care, Vol 2, Pp 85-92 (2011)

Previous studies have suggested that an arterial ammonia level greater than 150 mmol/L is highly sensitive for predicting subsequent development of cerebral edema in patients with fulminant liver failure. We performed a prospective cohort study to co

Externí odkaz: https://doaj.org/article/1aff0898a87e46c98bc285c9a834fa0d

Zobrazit plný text záznamu

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

Autor: Shiffman M. L., Suter F., Bacon B. R., Nelson D., Harley H., Sola R., Shafran S. D., Barange K., Lin A., Soman A., Zeuzem S., Crawford D., Leggett L., Roberts S., Weltman M., Greenbloom S., Menon K., Bourliere M., Brissot P., Bronowicki J. P., Doffoel M., Hezode C., Marcellin P., Tran A., Zarski J. P., Avci O., Berg T., Potthoff O., Rasenack J., Ross O., von Wagner M., Ascione A., Brunetto M., Bruno R., Bruno S., Cane E., Aguilar J., Barcena R., Diago M., Enriquez J., Garcia Samaniego J., Moreno R., Planas R., Rincon D., Testillano M., Anand B., Bilir B. Bahri, Balan V., Bank L., Barranco E., Berg C., Bernstein D., Bloom J., Bonkovsky H., Box T., Brau N., Bzowej N., Cassidy W., Clain D., Corasanti J., Davis M., DeJesus E., Delich P., Esposito S., Etzkorn K., Flora K., Fried M., Fromm H., Ghalib R., Gibas A., Godofsky E., Gompf S., Gordon S., Gordon F., Hammond G., Harrison S., Herrera J., Ho S., Howell C., Joshi S., Keeffe E., Kranz K., Kwo P., Lake Bakaar G., Larson A., Levin A., Lok A., Lucey M., Lyons M., Malet P., Malik P., Manch R., Mehra S., Mihas A., Mikolich D., Morgan T., Muir A., Nguyen R., Nunes D., Nyberg L., O'Brien C., Pappas S., Pauly M., Pedrosa M., Perkel M., Person J., Pockros P., Post A., Poulos J., Powell R., Raj V., Reed A., Reindollar R., Riley T., Rodriguez Torres M., Rubin R., Sahagun G., Schmidt W., Sepe T., Shaw Stiffel T., Sheikh A., Sherman K., Smith C., Stevens D., Sulkowski M., Toro D., Torres E., Tran T., Tsai N., Wohlman R., Wright W., Wruble L., Younossi Z., BRILLANTI, STEFANO

BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d06d4d125b5f21e735f5226014a1f0
http://hdl.handle.net/11365/1070791

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání